#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Invasive Zygomycosis of the Large Intestine in a Diabetes Patient


Authors: J. Bureš 1;  D. Codl 2;  D. Kodetová 3;  Z. Jech 4;  P. Hubáček 5
Authors‘ workplace: Klinika anesteziologie a resuscitace UK 2. LF a FN Motol MUDr. M. Pelichovská / Prof. MUDr. K. Cvachovec, CSc. 1;  Ústav lékařské mikrobiologie UK 2. LF a FN Motol, MUDr. O. Nyč 2;  Ústav patologie a molekulární medicíny UK 2. LF a FN Motol, prof. MUDr. R. Kodet, CSc. 3;  Chirurgická klinika UK 2. LF a FN Motol, prof. MUDr. J. Hoch, CSc. 4;  Klinika dětské hematologie a onkologie UK 2. LF a FN Motol, prof. MUDr. J. Starý, DrSc. 5
Published in: Rozhl. Chir., 2008, roč. 87, č. 8, s. 405-408.
Category: Monothematic special - Original

Overview

Invasive mucormycosis is a rare, serious or even fatal condition. The authors diagnosed and successfully treated the disorder in a 62-year-old diabetes patient. The course of the disease, including justification of the surgical procedure are described in the case review. All treatment options were implemented and, after 121 days of hospitalization, the patient was released for homecare.

Key words:
zygomycosis – mucormycosis – diabetes – colektomy – amphotericin B – complications


Sources

1. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., Edmond, M. B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis., 2004, Aug, l; 39(3): 309–317.

2. Alangadeh, G. J., Wahiduzzaman, M., Chandrasekar, P. H. Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin. Infect Dis., 2002, Sep, 15; 35(6): 659–664.

3. Marr, K. A., Carter, R. A., Crippa, F., Wald, A., Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect Dis., 2002, Apr, 1; 34(7): 909–917.

4. Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed. 2006;77 Suppl. 2: 32–35.

5. Chayakulkeeree, M., Ghannoum, M. A., Perfect, J. R. Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect Dis., 2006, Apr; 25(4): 215–229.

6. Chandrasekar, P. H., Ito, J. I. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin. Infect Dis., 2005, May, 1; 40 Suppl 6: S392–400.

7. Pagano, L., Girmenia, C., Mele, L., Ricci, P., Tosti, M. E., Nosari, A., et al. Infections caused by filamentous fungi in patients with hematologie malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica, 2001, Aug; 86(8): 862–870.

8. Pagano, L., Ricci, P., Tonso, A., Nosari, A., Cudillo, L., Montillo, M., et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell-ulto). Br. J. Haematol., 1997, Nov; 99(2): 331–336.

9. Khan, Z. U., Ahmad, S., Theyyathel, A. M. Detection of Aspergillus fumigatus-specific DNA, (1-3)-beta-d-glucan and galactomannan in serum and bronchoalveolar lavage specimens of experimentally infected rats. Mycoses, 2008, Mar; 51(2): 129–135.

10. Khan, Z. U., Ahmad, S., Theyyathel, A. M. Diagnostic value of DNA and (1-3)-beta-D-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with Fusarium oxysporum. J. Med. Microbiol., 2000, 8, Jan; 57 (Pt 1): 36–42.

11. Persat, F., Ranque, S., Derouin, F., Michel-Nguyen, A., Picot, S., Sulahian, A. Contribution of the (l-3)-beta-D-Glucan Assay for the Diagnosis of Invasive Fungal Infections. J. Clin. Microbiol., 2007, Dec 26.

12. Ahmad, S., Khan, Z., Mustafa, A. S., Khan, Z. U. Seminested PCR for diagnosis of candidemia: comparison with culture, antigen detection, and biochemical methods for species identification. J. Clin. Microbiol., 2002, Jul; 40(7): 2483–2489.

13. Mirhendi, H., Diba, K., Kordbacheh, P., Jalalizand, N., Makimura, K. Identification of pathogenic Aspergillus species by a PCR-restriction enzyme method. J. Med. Microbiol., 2007, Nov; 56(Pt 11): 1568–1570.

14. Rogers, T. R. Treatment of zygomycosis: current and new options. J. Antimicrob. Chemother., 2008, Jan; 61 Suppl. 1: 135–140.

15. Spellberg, B., Edwards, J. Jr., Ibrahim, A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev., 2005, Jul; 18(3): 556–569.

16. Walsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect Dis., 1998, Jun; 26(6): 1383–1396.

17. Groll, A. H., Walsh, T. J. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev. Anti Infect Ther., 2005, Aug; 3(4): 467–487.

18. Groll, A. H., Stergiopoulou, T., Roilides, E., Walsh, T. J. Micafungin: pharmacology, experimental therapeutics and clinical applications. Expert Opin. Investig. Druha, 2005, Apr; 14(4): 489–509.

19. Groll, A. H., Walsh, T. J. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly., 2002, Jun, 15; 132(23–24): 303–311.

20. Walsh, T. J., Viviani, M. A., Arathoon, E., Chiou, C., Ghannoum, M., Groll, A. H., et al. New targets and delivery systems for antifungal therapy. Med. Mycol., 2000; 38, Suppl 1: 335–347.

21. Groll, A. H., Muller, F. M., Piscitelli, S. C., Walsh, T. J. Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer. Klin. Padiatr., 1998, Jul-Aug; 210(4): 264–273.

22. Nakazato, T., Nagasaki, A., Nakayama, T., Shinhama, A., Taira, N,. Takasu, N. Sinonasal zygomycosis in a patient with myelodysplastic syndrome following non-myeloablative allogeneic peripheral blood stem cell transplantation. Intern. Med., 2007; 46(22): 1881–1882.

23. Ferguson A. D. Rhinocerebral mucormycosis acquired after a short course of prednisone therapy. J. Am. Osteopath. Assoc., 2007, Nov; 107(11): 491–493.

24. Mikesch, J. H., Rudat, A., Zuhlsdorf, M., Berdel, W. E., Mesters, R., Conrad, B., et al. Subcutaneous zygomycosis in neutropenia. J. Clin. Oncol., 2007, Oct; 20; 25(30): 4844–4845.

25. Trifilio, S., Singhal, S., Williams, S., Frankfurt, O., Gordon, L., Evens, A., et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant., 2007, Sep; 40(5): 451–456.

26. Jung, J. H., Choi, H. J., Yoo, J., Kang, S. J., Lee, K. Y. Emphysematous gastritis associated with invasive gastric mucormycosis: a case report. J. Korean Med. Sci., 2007, Oct; 22(5): 923–927.

27. Nosari, A., Oreste, P., Montillo, M., Carrafiello, G., Draisci, M., Muti, G., et al. Mucormycosis in hematologie malignancies: an emerging fungal infection. Haematologica, 2000, Oct; 85(10): 1068–1071.

28. Uckay, I., Chalandon, Y., Sartoretti, P., Rohner, P., Berney, T., Hadaya, K., et al. Invasive zygomycosis in transplant recipients. Clin. Transplant., 2007, Jul-Aug; 21(4): 577–582.

29. Ho, P. L, Yuen, K. Y. Aspergillosis in bone marrow transplant recipients. Crit. Rev. Oncol. Hematol., 2000, Apr; 34(l): 55–69.

30. Underhill, D., Braun, J. Current understanding of fungal microflora in inflammatory bowel disease pathogenesis. Inflamm. Bowel Dis., 2008, Feb 19.

31. Ibrahim A. S., Edwards, J. E. Jr., Fu, Y., Spellberg, B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J. Antimicrobial chemotherapy, 2006, Aug, 58: 1070–1073.

32. Roden, M. M., Zaoutis, T. E., Buchanan, W. L., et al. Epidemiology and outcome of zygomycosis:a review of 929 reported cases. Clin. Infect Dis., 2005, Sep, l; 41(5): 634–653.

Labels
Surgery Orthopaedics Trauma surgery
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#